伊立替康联合卡铂辅助化疗对宫颈癌患者血清叶酸、SCC-Ag水平及临床疗效的影响  

Effect of Irinotecan and Carboplatin Chemotherapy on the Serum Folicacid,SCC-Ag and Clinical Curative Effect of Cervical Cancer Patients

作　　者：伍立群[1] 李波[1] 肖凤仪[1] 方恋[1] 

机构地区：[1]湖北医药学院附属随州医院妇产科,湖北随州441300

出　　处：《标记免疫分析与临床》2017年第6期676-678,716,共4页Labeled Immunoassays and Clinical Medicine

摘　　要：目的探讨宫颈癌患者利用伊立替康联合卡铂辅助化疗时,患者血清叶酸、SCC-Ag水平及临床疗效的变化情况。方法选取2015年7月至2016年4月间于我院确诊的126例宫颈癌患者,随机分为两组,对照组60例患者直接进行广泛全子宫切除及盆腔淋巴结清扫术;实验组患者66例于术前进行卡铂与伊立替康的联合化疗,再行全子宫切除及盆腔淋巴结清扫术。治疗结束后,对两组患者的血清叶酸、SCC-Ag水平及临床治疗效果进行对比分析,并注意辅助化疗期间进行定期复查,记录毒副反应并给予相应治疗。结果实验组临床治疗有效率显著优于对照组,两组对比差异具有统计学意义(P<0.05);两组患者经治疗后血清叶酸水平均增高(P<0.05),实验组的SCC-Ag水平显著下降,且SCC-Ag水平低于对照组(P<0.05),实验组中发生骨髓抑制5例,胃肠道反应4例,脱发11例,切口感染2例,不良反应发生率为33.3%,对照组中发生切口感染4例,不良反应发生率为6.1%,两组的不良反应发生率比较差异有统计学意义(P<0.05)。结果对宫颈癌患者实施伊立替康联合卡铂辅助化疗能显著改善患者血清叶酸及SCC-Ag水平,虽然化疗会增加不良反应的发生率,但仍不失为提高临床疗效的重要手段。Objective To investigate the changes of serum folic acid, SCC-Ag and clinical curative effect in patients with cervical cancer under irinotecan treatment plus carboplatin chemotherapy.Methods 126 cases of cervical cancer patients from our hospital were selected and randomly divided into the control group and the experimental group.60 cases in the control group were treated by extensive hysterectomy and pelvic lymph node dissection.66 cases in the experiment group were treated by carboplatin and irinotecan.The clinical curative effect, serum folic acid and SCC-Ag levels were detected and compared between two groups.Results The clinical treatment effective rate in the experimental group was significantly better than the control group （P〈0.05）;after treatment, serum folic acid level after treatment in two groups were increased （P〈0.05）, experimental group SCC-Ag were significantly decreased, and the level of SCC-Ag was lower than that of control group （P〈0.05）.In the experimental group, there were 5 cases with bone marrow suppression, 4 cases with gastrointestinal reaction, 11 cases with alopecia, and 2 cases with incision infection.The incidence rate of adverse reaction was 33.3% in the control group.There were 4 cases with wound infection, and the incidence of adverse reaction was 6.1%.Comparing the two groups, the incidence was significant difference （P〈0.05）.Conclusion The implementation of irinotecan in combination with carboplatin chemotherapy can significantly improve serum folic acid level of SCC-Ag and irinotecan for patients with cervical cancer.Although chemotherapy can increase the incidence of adverse reaction, yet it is still an important method to improve the clinical curative effect.

关 键 词：伊立替康 卡铂 化疗 宫颈癌 血清叶酸 临床疗效 

分 类 号：R737.33[医药卫生—肿瘤]